会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Process for the preparation of indole derivatives
    • 吲哚衍生物的制备方法
    • US20050032875A1
    • 2005-02-10
    • US10487269
    • 2002-08-13
    • Heinz WollebAnnemarie WollebPaul Van Der SchaafRoman KollyNicole End
    • Heinz WollebAnnemarie WollebPaul Van Der SchaafRoman KollyNicole End
    • C07D209/12B01J31/18B01J31/24C07D209/24C07D319/06C07D405/06C07F5/02A61K31/405
    • C07D405/06C07D209/24C07D319/06C07F5/025Y02P20/55
    • A process for the preparation of compounds of formula (I) wherein R1 is unsubstituted or substituted C1-C8alkyl, R2, R3, R4 and R5 are each independently of the others hydrogen, unsubstituted or substituted C1-C8alkyl, C1-C8 alkoxy, phenoxy or benzyloxy, or halogen, Y1 and Y2 are each independently of the other hydrogen or a protecting group, or Y1 and Y2 together form a protecting bridge, and X1 is hydrogen, an organic radical or a cation, in which process a compound of formula (II) wherein R1 R2, R3, R4 and R5 are as defined above and Z1 is a leaving group, is reacted, in the presence of a catalytically effective amount of a palladium catalyst, with a compound of formula (III) wherein R6 is hydrogen, bromine, chlorine, iodine, —OSO2CF3, —COCI, —B(OH)2 or a mono- or di-ester derived from —B(OH)2, Y3 and Y4 are each a protecting group, or Y3 and Y4 together form a protecting bridge, and X1 is as defined above, to form a compound of formula (IV) and if desired the radicals Y3 and Y4 are converted into the radicals Y1 and Y2 where Y1 and Y2 are hydrogen.
    • 制备其中R 1为未取代或取代的C 1 -C 8烷基,R 2,R 3,R 4和R 5的式(I)化合物的方法各自独立地为氢,未取代或取代的C 1 -C 8烷基,C 1 -C 8烷氧基,苯氧基 或苄氧基或卤素,Y1和Y2各自独立地为另一个氢或保护基,或Y1和Y2一起形成保护桥,并且X 1是氢,有机基团或阳离子,其中式 (II)其中R1 R2,R3,R4和R5如上定义,Z1是离去基团,在催化有效量的钯催化剂存在下,与式(III)化合物反应,其中R 6是 氢,溴,氯,碘,-OSO 2 CF 3,-COCI,-B(OH)2或衍生自-B(OH)2,Y 3和Y 4的单酯或二酯各自为保护基,或Y 3和Y 4 一起形成保护桥,X1如上所定义,形成式(IV)的化合物,如果需要,基团Y 3和Y 4是 转化为Y1和Y2基团,其中Y1和Y2是氢。
    • 3. 发明申请
    • Electroluminescent Metal Complexes With Triazoles
    • 电子发光金属配合物与三唑
    • US20090062560A1
    • 2009-03-05
    • US12086646
    • 2006-12-18
    • Roger PretotRoman KollyThomas SchaferPaul Adriaan Van Der Schaaf
    • Roger PretotRoman KollyThomas SchaferPaul Adriaan Van Der Schaaf
    • C07F17/02
    • C09K11/06C07F15/0033C09K2211/1059C09K2211/185H01L51/0085H01L51/5016H05B33/14
    • Disclosed are electroluminescent metal complexes with triazoles of the formula (I), where n1 is an integer of 1 to 3, m1 and m2 each are an integer 0, 1 or 2, M1 is a metal with an atomic weight of greater than 40, L1 is a monodentate ligand or a bidentate ligand, L2 is a monodentate ligand, Q2 stands for an organic bridging group completing, together with the bonding carbon atoms of the triazole ring, an annellated, carbocyclic or heterocyclic, non-aromatic ring, which optionally may be substituted, Q3 represents a group of forming a condensed aromatic, or heteroaromatic ring, which can optionally be substituted, as well as new intermediates for the preparation of these complexes, electronic devices comprising the metal complexes and their use in electronic devices, especially organic light emitting diodes (OLEDs), as oxygen sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts.
    • 公开了具有式(I)的三唑的电致发光金属络合物,其中n1为1〜3的整数,m1和m2各自为整数0,1或2,M1为原子量大于40的金属, L1是单齿配体或二齿配体,L2是单齿配体,Q2表示完全有机桥基,连同三唑环的键合碳原子,环状的,碳环或杂环的非芳香环,其任选地 可以被取代,Q3表示形成稠合芳族或可以任意被取代的杂芳环的基团,以及用于制备这些络合物的新中间体,包含金属络合物的电子器件及其在电子器件中的用途,特别是 有机发光二极管(OLED)作为氧敏感指标,作为生物测定中的磷光指示剂,以及作为催化剂。
    • 5. 发明授权
    • Process for the preparation of ketimines
    • 酮亚胺的制备方法
    • US06693218B1
    • 2004-02-17
    • US10130199
    • 2002-09-20
    • Marc ThommenAndreas HafnerRoman KollyHans-Jörg KirnerFrédéric Brunner
    • Marc ThommenAndreas HafnerRoman KollyHans-Jörg KirnerFrédéric Brunner
    • C07C24902
    • C07C249/02C07C251/20
    • Described is a process for the preparation of compounds of formula (1a) which comprises reacting an isomeric mixture consisting of from 75 to 95% of compound of formula (2a) and from 5 to 25% of a compound of formula (2b) with methylamine, in a suitable solvent, to form a sertraline-imine isomeric mixture consisting of from 75 to 95% of formula (1a) and from 5 to 25% of formula (1b)(A1), or reacting an isomeric mixture consisting of from 75 to 95% of a compound of formula (2a) and from 5 to 25% of a compound of formula (2b) with methylamine, in a suitable solvent, using suitable methods of isolation to form an enriched sertraline-imine isomeric mixture, consisting of >99% of a compound of formula (1a) and
    • 描述了制备式(1a)化合物的方法,其包括将由75至95%的式(2a)化合物和5至25%的式(2b)化合物组成的异构体混合物与甲胺 在合适的溶剂中形成由75至95%的式(1a)和5至25%的式(1b)(A1)组成的舍曲林 - 亚胺异构体混合物,或将由75 至95%的式(2a)化合物和5至25%的式(2b)化合物与甲胺在合适的溶剂中,使用合适的分离方法形成富集的舍曲林 - 亚胺异构体混合物,其由 > 99%的式(1a)化合物和<1%式(1b)化合物(A2)的化合物; 然后根据反应路线(A1)或(A2)得到的舍曲林 - 亚胺异构体混合物在合适的溶剂中,按照式(Ⅰ)中式(Ⅰa)中R1,R2 和R 3各自独立地为氢,卤素,三氟甲基或C 1 -C 4烷氧基,式(1b),(2a​​)和(2b)如说明书中所定义。